Current Report Filing (8-k)
September 24 2019 - 7:22AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 8-K
_________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): September 24, 2019
_________________________
Protalix
BioTherapeutics, Inc.
(Exact name of registrant as specified
in its charter)
_________________________
Delaware
|
|
001-33357
|
|
65-0643773
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
2 Snunit Street
|
|
20100
|
Science Park, POB 455
|
|
|
Carmiel, Israel
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code +972-4-988-9488
(Former name or former address, if changed
since last report.)
_________________________
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth
company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section
12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name of
each exchange on which registered
|
Common stock, $0.001 par value
|
|
PLX
|
|
NYSE American
|
On September 24, 2019, Protalix BioTherapeutics, Inc.
(the “Company”) issued a press release in which the Company and its development and commercialization partner, Chiesi
Farmaceutici S.p.A., announced the completion of enrollment in the Company’s phase III BALANCE clinical trial of pegunigalsidase
alfa (PRX-102) for the treatment of Fabry disease, via intravenous (IV) infusions of 1 mg/kg
administered every 2 weeks. PRX-102 is the Company’s proprietary pegunigalsidase alfa,
an investigational, plant cell culture expressed enzyme, and a chemically modified version of, the recombinant alpha-Galactosidase-A
protein. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K
and is incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 24, 2019
|
PROTALIX BIOTHERAPEUTICS, INC.
|
|
|
|
|
|
By:
|
/s/ Dror Bashan
|
|
|
Name:
|
Dror Bashan
|
|
|
Title:
|
President and
|
|
|
|
Chief Executive Officer
|
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Sep 2023 to Sep 2024